Asymmetric dimethyl arginine levels in chronic hemodialysis patients

To investigate serum asymmetric dimethyl arginine (ADMA) levels in maintenance hemodialysis (HD) patients and to assess their potential correlations with C-reactive protein (CRP), albumin, and cholesterol levels as the established cardiovascular and nutritional parameters. Materials and methods: Forty-nine patients on maintenance HD treatment and 22 healthy volunteers with similar age and sex characteristics were recruited into the study. Serum albumin, CRP, creatinine, calcium, phosphate, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, hemoglobin, white blood cell counts, and serum ADMA levels were measured. Results: HD patients had significantly higher ADMA levels compared with healthy controls (0.51 ± 0.25 vs. 0.35 ± 0.15, P = 0.002). While white blood cell counts and body mass index values were similar between the 2 groups, CRP and LDL cholesterol were significantly higher and albumin and HDL cholesterol were significantly lower in HD patients compared with healthy controls. ADMA concentrations were positively correlated with mean age (P = 0.02, r = 0.360), LDL cholesterol levels (P = 0.006, r = 0.325), and CRP levels (P = 0.02, r = 0.268) and negatively correlated with serum albumin levels (P = 0.005, r = –0.331). Conclusion: ADMA levels were found to be higher in HD patients and were shown to be correlated with preestablished inflammatory and nutritional biomarkers.

Anahtar Kelimeler:

Key words: Chronic kidney disease, asymmetric dimethyl arginine, ADMA, endothelial dysfunction, atherosclerosis, hemodialysis

Asymmetric dimethyl arginine levels in chronic hemodialysis patients

Keywords:

Key words: Chronic kidney disease, asymmetric dimethyl arginine, ADMA, endothelial dysfunction, atherosclerosis, hemodialysis,

PDF

___

Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: 112–119.
Recio-Mayoral A, Banerjee D, Streather C, Kaski JC. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease - a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011; 216: 446–451.
Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14: 1927–1939.
Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291–297.
Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006; 147: 193–201.
Simko F, Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol Res 2000; 49: 37–
Kielstein JT, Fliser D. The past, presence and future of ADMA in nephrology. Nephrol Ther 2007; 3: 47–54.
Ebinc FA, Erten Y, Ebinc H, Pasaoglu H, Demirtas C, Tacoy G, Mutluay R, Koc E, Derici U, Reis KA et al. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients. Ren Fail 2008; 30: 401– 40
Uzun H, Konukoglu D, Besler M, Erdenen F, Sezgin C, Muderrisoglu C. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clin Invest Med 2008; 31: 1–7.
Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62: 339–345.
Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186–202.
Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113–2117.
Cupisti A, Saba A, D’Alessandro C, Meola M, Panicucci E, Panichi V, Raffaelli A, Barsotti G. Dimethylarginine levels and nutritional status in hemodialysis patients. J Nephrol 2009; 22: 623–629.
Zhang DL, Liu J, Liu S, Zhang Y, Liu WH. The differences of asymmetric dimethylarginine removal by different dialysis treatments. Ren Fail 2010; 32: 935–940.
El-Mesallamy HO, Abdel Hamid SG, Gad MZ. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake. Kidney Blood Press Res 2008; 31: 189–195.
Terekeci HM, Oktenli C, Ozgurtas T, Nalbant S, Top C, Celik S, Tapan S, Kucukardali Y, Sanisoglu YS, Solmazgul E et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol 2008; 35: 2024–2029.
Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2α (8-iso-PGF2α) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16: 52–
Tripepi G, Mattace Raso F, Sijbrands E, Seck MS, Maas R, Boger R, Witteman J, Rapisarda F, Malatino L, Mallamaci F et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 2011; 6: 1714–1721.
Coen G, Mantella D, Sardella D, Beraldi MP, Ferrari I, Pierantozzi A, Lippi B, Di Giulio S. Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients. J Nephrol 2009; 22: 616–622.
Palomo I, Contreras A, Alarcon LM, Leiva E, Guzman L, Mujica V, Icaza G, Diaz N, Gonzalez DR, Moore-Carrasco R. Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide 2011; 24: 224–228.
Alsagaff MY, Thaha M, Aminuddin M, Yogiarto RM, Yogiantoro M, Tomino Y. Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J Int Med Res 2012; 40: 340–349.
Aucella F, Maas R, Vigilante M, Tripepi G, Schwedhelm E, Margaglione M, Gesualdo L, Boeger R, Zoccali C. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis 2009; 207: 541–545.